This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boucher, B. A.
Right arrow Articles by Hess, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boucher, B. A.
Right arrow Articles by Hess, M. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 1998, p. 930-933, Vol. 42, No. 4
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Fluconazole Pharmacokinetics in Burn Patients

Bradley A. Boucher,1,* Stephen R. King,2 Heidi L. Wandschneider,3 William L. Hickerson,2 Scott D. Hanes,1 Vanessa L. Herring,1 Todd W. Canada,4 and Mary M. Hess5

Department of Clinical Pharmacy1 and Department of Plastic Surgery,2 University of Tennessee, Memphis, Tennessee 38163; Department of Pharmacy Services, University of Wisconsin Hospitals and Clinics, Madison, Wisconsin 537923; Department of Pharmacy Services, Parkland Health & Hospital System, Dallas, Texas 752354; and Department of Pharmacy Practice, University of Pittsburgh, Pittsburgh, Pennsylvania 152135

Received 15 May 1997/Returned for modification 8 October 1997/Accepted 23 December 1997

The pharmacokinetics of fluconazole in nine adult patients with severe (30 to 95% total body surface area) burns were studied. There was no significant difference in half-life (t1/2), clearance (CL), or volume of distribution (V) over time in five patients on days 3 and 8 of the study (P > 0.05). Combined parameter estimates (means ± standard deviations) for all nine patients for the two study periods were as follows: t1/2, 24.4 ± 5.8 h; CL, 0.36 ± 0.09 ml/min/kg; and V, 0.72 ± 0.12 liters/kg. These estimates of t1/2 and CL in burn patients were approximately 13% shorter and 30% more rapid, respectively, than the most extreme estimates reported for other populations.

* Corresponding author. Mailing address: Department of Clinical Pharmacy, University of Tennessee, Memphis, 26 South Dunlap, Room #202, Memphis, TN 38163. Phone: (901) 448-6500. Fax: (901) 448-6064. E-mail: bboucher{at}utmem1.utmem.edu.

Antimicrobial Agents and Chemotherapy, April 1998, p. 930-933, Vol. 42, No. 4
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Pasqualotto, A C, Shah, M, Wynn, R, Denning, D W (2008). Voriconazole plasma monitoring. Arch. Dis. Child. 93: 578-581 [Abstract] [Full Text]  
  • Kiser, T. H., Hoody, D. W., Obritsch, M. D., Wegzyn, C. O., Bauling, P. C., Fish, D. N. (2006). Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.. Antimicrob. Agents Chemother. 50: 1937-1945 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»